Daré Bioscience, Inc. (DARE) Bundle
A Brief History of Daré Bioscience, Inc. (DARE)
Foundation and Early Years
Daré Bioscience, Inc. was founded in 2016. The company was established with a focus on developing innovative therapeutic solutions for women's health. Headquartered in San Diego, California, Daré is publicly traded on the Nasdaq under the ticker symbol DARE.
Key Product Developments
One of the prominent products developed by Daré is Xaciato (drosperinone and ethinyl estradiol), which received FDA approval in November 2020. This product is aimed at addressing conditions related to hormonal imbalance.
In addition, Daré is advancing its pipeline with several investigational product candidates, including:
- DARE-BV1 - A treatment for bacterial vaginosis.
- DARE-HRT1 - A hormone replacement therapy.
- DARE-CC1 - An investigational vaginal ring for contraception.
Financial Performance
As of the end of 2022, Daré Bioscience reported revenues of approximately $1.4 million, primarily from product sales. The total assets of the company were valued at around $34.1 million.
In the first half of 2023, the company reported a net loss of $9.8 million compared to a net loss of $7.5 million in the first half of 2022.
Stock Performance
As of October 2023, Daré Bioscience's stock price was approximately $0.50 per share, with a market capitalization of about $20 million.
Over the last 12 months, the stock has experienced volatility, with a 52-week range of $0.35 to $1.50.
Strategic Partnerships and Collaborations
In 2021, Daré entered into a collaboration with Womens Health Initiative for the development of a novel contraceptive product. This partnership is expected to leverage combined expertise in women’s health research to expedite product development timelines.
Regulatory Milestones
Daré has achieved major regulatory milestones, including:
- FDA Approval for Xaciato in November 2020.
- Orphan Drug Designation for DARE-BV1 in 2021.
- Fast Track Designation for DARE-HRT1 in March 2022.
| Year | Total Revenue ($) | Net Loss ($) | Total Assets ($) | Stock Price ($) |
|---|---|---|---|---|
| 2020 | 500,000 | -5,000,000 | 12,000,000 | 1.00 |
| 2021 | 1,000,000 | -6,000,000 | 20,000,000 | 0.80 |
| 2022 | 1,400,000 | -9,000,000 | 34,100,000 | 0.50 |
| 2023 (H1) | 750,000 | -9,800,000 | 30,000,000 | 0.50 |
Future Outlook
Daré is committed to advancing women's health solutions, with ongoing trials and product development across various therapeutic areas. The company aims to expand its market presence through innovative research and strategic partnerships.
A Who Owns Daré Bioscience, Inc. (DARE)
Key Shareholders
Key Shareholders
As of the latest available data, the ownership structure of Daré Bioscience, Inc. (DARE) consists primarily of institutional investors, individual stakeholders, and company insiders. The following table illustrates the major shareholders and their respective ownership percentages:
| Shareholder Type | Name | Ownership Percentage | Shares Owned |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 8.54% | 1,978,796 |
| Institutional Investor | Geode Capital Management, LLC | 5.75% | 1,357,580 |
| Institutional Investor | The Vanguard Group, Inc. | 4.59% | 1,073,855 |
| Individual Insider | Erin A. Duffy | 1.85% | 431,300 |
| Individual Insider | Michael E. A. O'Connell | 1.10% | 256,712 |
Recent Stock Performance
The stock performance of Daré Bioscience, Inc. (DARE) is also pivotal in understanding shareholder value. As of the latest trading data:
| Date | Closing Price ($) | Market Capitalization ($ million) | Volume |
|---|---|---|---|
| October 20, 2023 | 1.25 | 94.87 | 250,000 |
| October 19, 2023 | 1.22 | 93.57 | 300,000 |
| October 18, 2023 | 1.20 | 92.27 | 200,000 |
Insider Transactions
Insider trading activity provides insight into the confidence company executives have in the future of Daré Bioscience, Inc. The following table highlights recent insider transactions:
| Date | Insider Name | Transaction Type | Shares Transacted | Price ($) |
|---|---|---|---|---|
| September 15, 2023 | Erin A. Duffy | Buy | 50,000 | 1.10 |
| August 22, 2023 | Michael E. A. O'Connell | Sell | 20,000 | 1.15 |
| July 12, 2023 | Erin A. Duffy | Buy | 10,000 | 1.05 |
Shareholder Meeting Outcomes
Recent shareholder meetings have addressed critical company strategies and shareholder proposals. Key decisions include:
- Approval of the 2023 Equity Incentive Plan
- Re-election of Board Members
- Ratification of the appointment of independent auditors for 2024
Research and Development Funding
Daré Bioscience has actively sought funding for its research and development initiatives. Funding milestones include:
- Raised $20 million in a public offering in June 2023
- Secured $5 million in grants for women's health product development in September 2023
Current Financial Metrics
As of the most recent financial disclosure, Daré Bioscience, Inc. reported the following metrics:
| Metric | Value |
|---|---|
| Total Assets ($ million) | 30.5 |
| Total Liabilities ($ million) | 8.7 |
| Revenue ($ million) | 1.2 |
| Net Loss ($ million) | (6.1) |
Daré Bioscience, Inc. (DARE) Mission Statement
Company Overview
Daré Bioscience, Inc. (NASDAQ: DARE) focuses on advancing innovative therapies in women's health. The company is committed to addressing unmet medical needs through the development of therapeutics that enhance the quality of life for women. The mission statement encapsulates their aim to empower women by providing effective and safe healthcare solutions.
Core Values
- Innovation: Dedication to groundbreaking research and development.
- Integrity: Upholding ethical standards in all operations.
- Collaboration: Working with healthcare professionals and stakeholders.
- Patient-Centric: Focusing on patients' needs and outcomes.
- Excellence: Striving for the highest standards in product development.
Financial Performance
As of Q2 2023, Daré Bioscience reported financials highlighting their growth trajectory:
| Financial Metric | Q2 2023 Amount | Q2 2022 Amount |
|---|---|---|
| Total Revenue | $1.2 million | $900,000 |
| Net Loss | $(6.0) million | $(5.7) million |
| Cash and Cash Equivalents | $18.5 million | $10.7 million |
| Total Assets | $24.3 million | $15.0 million |
| Shares Outstanding | 20.4 million | 16.5 million |
Pipeline Development
Daré Bioscience has a robust pipeline aimed at delivering innovative therapies:
| Product Candidate | Indication | Stage of Development |
|---|---|---|
| DARE-BV | Bacterial Vaginosis | Phase 3 |
| DARE-FRT | Female Sexual Dysfunction | Phase 2 |
| DARE-NEP | Endometriosis | Preclinical |
| DARE-DF | Pelvic Floor Disorders | Phase 1 |
Strategic Partnerships
To enhance their mission, Daré Bioscience has established strategic partnerships:
- Partnership with University of Texas: Focused on research in women's health.
- Collaboration with Cognition Therapeutics: Enhancing drug discovery capabilities.
- Alliance with Medtronic: Exploring novel delivery mechanisms.
Recent Milestones
Recent achievements underscore the commitment to their mission:
| Date | Milestone |
|---|---|
| March 2023 | Initiated Phase 3 trial for DARE-BV. |
| May 2023 | Received FDA Fast Track designation for DARE-FRT. |
| July 2023 | Hosted community outreach program to raise awareness on women’s health issues. |
How Daré Bioscience, Inc. (DARE) Works
Company Overview
Company Overview
Daré Bioscience, Inc. (DARE) is a clinical-stage biopharmaceutical company focused on advancing innovative therapeutics for women's health. The company aims to address unmet medical needs through the development of various drug candidates for conditions such as contraception, menopause, and reproductive health.
Business Model
Daré operates primarily in the field of women's health, leveraging its proprietary technologies and partnerships to develop products. The business model is centered around:
- Research and development investment.
- Collaboration with other pharmaceutical companies.
- Licensing agreements for product commercialization.
- Focus on regulatory approvals for drug candidates.
Financial Performance
As of the third quarter of 2023, Daré Bioscience reported the following financial results:
| Metric | Q3 2023 Amount | Q3 2022 Amount |
|---|---|---|
| Revenue | $1.2 million | $0.5 million |
| Net Loss | $(5.1) million | $(4.3) million |
| Operating Expenses | $6.3 million | $5.2 million |
| Cash and Cash Equivalents | $15.6 million | $12 million |
Research and Development Pipeline
Daré's pipeline includes several product candidates at different stages of development. The most notable include:
| Product Candidate | Indication | Stage of Development |
|---|---|---|
| YooMee | Contraception | Phase 3 |
| DFE-215 | Menopausal Symptoms | Phase 2 |
| DARE-HRT1 | Hormone Replacement Therapy | Phase 1 |
| DARE-API | Endometriosis | Preclinical |
Strategic Partnerships
Daré collaborates with various organizations to enhance development and commercialization capabilities, focusing on:
- Partnering with larger pharmaceutical companies for shared expertise.
- Engaging in academic collaborations for research purposes.
- Negotiating licensing agreements to expand market reach.
Regulatory Strategy
Daré's regulatory strategy involves:
- Submissions of Investigational New Drug (IND) applications.
- Engaging with the FDA for guidance throughout the development process.
- Preparing for New Drug Application (NDA) submissions upon successful completion of clinical trials.
Market Position
As of 2023, Daré Bioscience holds a market capitalization of approximately $40 million. The company positions itself uniquely within a market that is projected to grow, with the global women's health market expected to reach $34 billion by 2025.
Stock Performance
The stock performance of DARE as of late October 2023 shows:
| Date | Stock Price ($) | Market Cap ($ million) |
|---|---|---|
| October 27, 2023 | $1.52 | $38.5 |
| October 20, 2023 | $1.45 | $37.0 |
| October 13, 2023 | $1.60 | $40.0 |
| October 6, 2023 | $1.55 | $39.5 |
Future Outlook
Daré Bioscience is focused on achieving significant milestones, including:
- Completion of ongoing clinical trials.
- Submission of regulatory applications.
- Expanding its product pipeline through innovative research.
How Daré Bioscience, Inc. (DARE) Makes Money
Product Development and Sales
Daré Bioscience focuses on developing innovative products primarily for women's health. Their revenue generation is largely dependent on the successful commercialization of their proprietary products. The company is advancing its pipeline of products targeting various conditions such as contraception, endometriosis, and sexual health disorders. Their key products include:
- Intravaginal ring (IVR)
- Topical formulations
- Oral contraceptives
Partnerships and Collaborations
Daré Bioscience engages in partnerships with larger pharmaceutical companies to leverage their resources for the development and commercialization of products. Notable partnerships include:
- Strategic Partnership with Bayer AG: A collaboration for the development of innovative contraceptive methods.
- Licensing agreements: These often involve upfront payments and milestone payments based on the development stages.
Financial Performance Metrics
As of the second quarter of 2023, Daré Bioscience reported the following financial performance metrics:
| Metric | Value |
|---|---|
| Revenue (Q2 2023) | $1.5 million |
| Net Loss (Q2 2023) | $(3.2) million |
| Cash Position (End of Q2 2023) | $10.5 million |
| Total Assets | $15.1 million |
| Total Liabilities | $4.6 million |
Grants and Funding
Daré Bioscience benefits from various grants and funding sources, aiding in the development of their product pipeline. In 2022, they received a substantial grant from the National Institutes of Health (NIH) amounting to:
- $2 million
Market Position and Competition
In the women's health sector, Daré competes with established firms and new entrants. The global market for women's health products was valued at approximately:
- $40 billion in 2022
- Expected to grow at a CAGR of 5.5% from 2023 to 2030
Daré’s niche focus enables them to identify unmet medical needs, setting them apart in the competitive landscape.
Future Revenue Streams
Daré Bioscience is actively pursuing future revenue streams through:
- Expanding product portfolio with additional indications
- Exploring international markets
- Enhancing direct-to-consumer sales strategies
Valuation and Stock Performance
As of October 2023, Daré Bioscience (DARE) had a market capitalization of approximately:
- $50 million
- Stock Price: $0.85 per share
The company’s stock performance reflects investor sentiment towards their product pipeline and strategic initiatives.
Daré Bioscience, Inc. (DARE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support